A Phase 3 interventional study of Faricimab and Aflibercept in Macular Edema, Central Retinal Vein Occlusion and Hemiretinal Vein Occlusion, sponsored by Hoffmann-La Roche. Completed at 194 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing faricimab in Macular Edema — 1 open to participants now, 3 under way, none of them phase 3. faricimab · Macular Edema.
Among the 13 studies testing faricimab in Macular Edema, this one is the 4th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 3, and was the 7th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →1 of the 13 studies testing faricimab in Macular Edema is open now. Recruiting first, the newest first:
Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust
Ages 18+
faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2021.
This study's enrollment of 729 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 229 across the 13 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 13 have an industry lead sponsor. The 6 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
28 studies in Macular Edema by Hoffmann-La Roche: 1 open now, 5 under way, 1 of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 4th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 15th registered.
Hoffmann-La Roche’s Macular Edema studies by the year they started, since 2007.
2 of the studies testing faricimab in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05610319McMaster UniversityTreat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial | 2026-12 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing faricimab in Macular Edema, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 28 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in patients with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ocular Exclusion Criteria for Study Eye:
Ocular Exclusion Criteria for Both Eyes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
Drug: Faricimab · Procedure: Sham Procedure
In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).
Drug: Faricimab · Drug: Aflibercept · Procedure: Sham Procedure
Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
Also known as: VABYSMO®, faricimab-svoa, RG7716, RO6867461
Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
Also known as: Eylea
The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
Time frame: From Baseline through Week 24
Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: From Baseline through Week 24
Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\>38 and ≤38 letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 24
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the Bruch's membrane (BM) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 24
Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 24
Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24
Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24
Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part 1: Change From Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24
The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the ANCOVA analysis, the model uses the non-missing change from baseline in BCVA at Weeks 24 as the response variables adjusted for the treatment group, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA score (≥55 and ≤54 letters) and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were not imputed. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline and Week 24
Parts 1 and 2: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\>38 and ≤38 letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Change From Baseline in NEI VFQ-25 Questionnaire Composite Score at Specified Timepoints Through Week 72
The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the MMRM analysis, the model adjusted for the treatment group, visit, visit-by-treatment group interaction, baseline NEI VFQ-25 Composite Score continuous), baseline BCVA score (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were implicitly imputed. Invalid BCVA values were excluded. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 24, 48, and 72
Parts 1 and 2: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 72
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 72
Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 72
Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72
Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72
Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Part 2: Change From Week 24 in BCVA in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Part 2: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Part 2: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Part 2: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Part 2: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Part 2: Percentage of Participants on Different Treatment Intervals at Week 68
In Part 2 of the study, participants in both the faricimab Q4W and aflibercept Q4W arms in Part 1 received 6 mg faricimab intravitreal injections administered according to a personalized treatment interval (PTI) dosing regimen in intervals between Q4W and Q16W. At faricimab dosing visits, treatment intervals were maintained or adjusted (i.e., increased by 4 weeks or decreased by 4, 8, or 12 weeks), based on central subfield thickness (CST) and BCVA values.
Time frame: Week 68
Part 2: Number of Study Drug Injections Received in the Study Eye From Week 24 Through Week 72
Time frame: From Week 24 to Week 72
Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale
This analysis of adverse events (AEs) only includes ocular AEs that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).
Time frame: Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72
Incidence of Ocular Adverse Events in the Fellow Eye
This analysis of adverse events (AEs) only includes ocular AEs that occurred in the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).
Time frame: Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72
Incidence of Non-Ocular Adverse Events
This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
Time frame: Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72
Plasma Concentration of Faricimab Over Time
Time frame: Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72
Number of Participants With Anti-Drug Antibodies (ADAs) to Faricimab at Baseline and Post-Baseline During the Study
Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The number of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period. Treatment-unaffected ADA-positive is a post-baseline sample with a titer that is lower than 4-fold the ADA-positive baseline titer (faricimab arm) or the ADA-positive titer prior to first faricimab injection (aflibercept arm).
Time frame: Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72
| Milestone | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Started | 366 | 363 |
| Received at least one dose of study drug | 365 | 361 |
| Completed | 360 | 353 |
| Not completed | 6 | 10 |
| Withdrew: Withdrawal by subject | 0 | 4 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Non-compliance with study drug | 2 | 0 |
| Withdrew: Reason not specified | 2 | 0 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Milestone | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Started | 360 | 353 |
| Completed | 333 | 323 |
| Not completed | 27 | 30 |
| Withdrew: Withdrawal by subject | 11 | 11 |
| Withdrew: Lost to follow-up | 3 | 9 |
| Withdrew: Adverse event | 5 | 5 |
| Withdrew: Death | 4 | 1 |
| Withdrew: Other | 1 | 3 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
| ETDRS Letters | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 | 16.9 (15.4 to 18.3) | 17.3 (15.9 to 18.8) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
| ETDRS Letters | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 13.5 (12.5 to 14.6) | 14.3 (13.2 to 15.4) |
| Week 8 | 15.5 (14.4 to 16.7) | 16.5 (15.3 to 17.7) |
| Week 12 | 16.9 (15.7 to 18.2) | 17.1 (15.8 to 18.4) |
| Week 16 | 16.8 (15.4 to 18.1) | 17.5 (16.2 to 18.9) |
| Week 20 | 17.0 (15.6 to 18.3) | 17.2 (15.8 to 18.5) |
| Week 24 | 16.9 (15.4 to 18.3) | 17.3 (15.9 to 18.8) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Week 24 | 56.6 (51.7 to 61.5) | 58.1 (53.3 to 62.9) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 41.5 (36.7 to 46.3) | 45.4 (40.7 to 50.2) |
| Week 8 | 51.1 (46.3 to 55.9) | 53.7 (48.9 to 58.5) |
| Week 12 | 54.6 (49.8 to 59.4) | 55.1 (50.3 to 59.9) |
| Week 16 | 57.7 (52.8 to 62.5) | 59.5 (54.7 to 64.3) |
| Week 20 | 56.6 (51.7 to 61.4) | 57.8 (53.0 to 62.6) |
| Week 24 | 56.6 (51.7 to 61.5) | 58.1 (53.3 to 62.9) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 60.9 (56.0 to 65.8) | 62.3 (57.6 to 66.9) |
| Week 8 | 69.1 (64.5 to 73.7) | 72.8 (68.3 to 77.2) |
| Week 12 | 73.2 (68.8 to 77.7) | 74.7 (70.3 to 79.0) |
| Week 16 | 73.5 (69.1 to 78.0) | 75.8 (71.4 to 80.1) |
| Week 20 | 72.4 (68.0 to 76.9) | 74.1 (69.7 to 78.5) |
| Week 24 | 72.2 (67.7 to 76.6) | 73.3 (68.8 to 77.7) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 83.1 (79.3 to 86.9) | 83.5 (79.7 to 87.2) |
| Week 8 | 85.2 (81.7 to 88.8) | 86.8 (83.3 to 90.2) |
| Week 12 | 87.4 (84.1 to 90.8) | 87.1 (83.7 to 90.5) |
| Week 16 | 86.3 (82.9 to 89.8) | 88.7 (85.5 to 92.0) |
| Week 20 | 84.1 (80.5 to 87.8) | 86.5 (83.0 to 90.0) |
| Week 24 | 85.3 (81.8 to 88.8) | 84.6 (80.9 to 88.2) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 92.1 (89.4 to 94.8) | 95.6 (93.5 to 97.7) |
| Week 8 | 92.1 (89.4 to 94.8) | 94.8 (92.5 to 97.0) |
| Week 12 | 93.2 (90.6 to 95.7) | 92.6 (89.9 to 95.2) |
| Week 16 | 92.6 (90.0 to 95.3) | 92.0 (89.3 to 94.8) |
| Week 20 | 90.5 (87.5 to 93.4) | 91.4 (88.6 to 94.3) |
| Week 24 | 90.5 (87.5 to 93.4) | 89.2 (86.1 to 92.4) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 98.4 (97.1 to 99.7) | 98.9 (97.8 to 100.0) |
| Week 8 | 98.1 (96.7 to 99.5) | 98.1 (96.7 to 99.5) |
| Week 12 | 98.6 (97.5 to 99.8) | 97.5 (95.9 to 99.1) |
| Week 16 | 97.3 (95.6 to 98.9) | 97.0 (95.2 to 98.7) |
| Week 20 | 97.0 (95.3 to 98.7) | 96.7 (94.9 to 98.5) |
| Week 24 | 96.2 (94.3 to 98.1) | 96.7 (94.9 to 98.5) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 98.1 (96.7 to 99.5) | 98.6 (97.4 to 99.8) |
| Week 8 | 97.5 (96.0 to 99.1) | 97.5 (95.9 to 99.1) |
| Week 12 | 97.8 (96.3 to 99.3) | 97.0 (95.2 to 98.7) |
| Week 16 | 95.9 (93.9 to 97.9) | 96.1 (94.2 to 98.1) |
| Week 20 | 96.7 (94.9 to 98.5) | 96.1 (94.2 to 98.1) |
| Week 24 | 95.1 (92.9 to 97.3) | 95.9 (93.8 to 97.9) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 97.0 (95.3 to 98.7) | 98.1 (96.7 to 99.5) |
| Week 8 | 96.2 (94.2 to 98.1) | 96.4 (94.5 to 98.3) |
| Week 12 | 95.9 (93.9 to 97.9) | 96.1 (94.2 to 98.1) |
| Week 16 | 95.4 (93.2 to 97.5) | 94.8 (92.5 to 97.0) |
| Week 20 | 94.8 (92.6 to 97.1) | 93.9 (91.5 to 96.4) |
| Week 24 | 94.0 (91.6 to 96.4) | 93.7 (91.2 to 96.1) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 6.0 (3.6 to 8.4) | 4.7 (2.6 to 6.8) |
| Week 8 | 8.7 (5.9 to 11.5) | 10.2 (7.2 to 13.2) |
| Week 12 | 10.9 (7.8 to 14.0) | 11.9 (8.7 to 15.0) |
| Week 16 | 11.5 (8.4 to 14.6) | 14.1 (10.7 to 17.5) |
| Week 20 | 14.2 (10.9 to 17.6) | 14.9 (11.4 to 18.3) |
| Week 24 | 14.5 (11.0 to 17.9) | 15.2 (11.7 to 18.7) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 45.0 (41.0 to 49.1) | 46.1 (41.9 to 50.2) |
| Week 8 | 48.6 (44.3 to 52.8) | 54.6 (50.5 to 58.7) |
| Week 12 | 54.9 (50.8 to 58.9) | 55.7 (51.4 to 60.0) |
| Week 16 | 54.9 (50.6 to 59.1) | 59.3 (55.2 to 63.4) |
| Week 20 | 54.1 (49.7 to 58.4) | 57.6 (53.4 to 61.8) |
| Week 24 | 55.7 (51.3 to 60.0) | 59.0 (54.5 to 63.4) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\>38 and ≤38 letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 10.0 (7.3 to 12.8) | 8.6 (6.1 to 11.1) |
| Week 8 | 8.2 (5.5 to 10.8) | 7.0 (4.6 to 9.4) |
| Week 12 | 7.3 (4.9 to 9.8) | 6.4 (4.0 to 8.8) |
| Week 16 | 7.8 (5.3 to 10.4) | 6.2 (3.8 to 8.5) |
| Week 20 | 8.4 (5.7 to 11.0) | 6.4 (4.0 to 8.8) |
| Week 24 | 10.1 (7.1 to 13.0) | 7.5 (4.9 to 10.1) |
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the Bruch's membrane (BM) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
| microns | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | -420.8 (-429.2 to -412.5) | -417.3 (-425.6 to -409.0) |
| Week 8 | -444.2 (-452.7 to -435.7) | -437.5 (-446.1 to -429.0) |
| Week 12 | -451.0 (-460.6 to -441.5) | -442.5 (-452.1 to -433.0) |
| Week 16 | -452.5 (-461.8 to -443.1) | -445.2 (-454.7 to -435.8) |
| Week 20 | -459.4 (-467.8 to -451.0) | -445.1 (-453.6 to -436.6) |
| Week 24 | -461.6 (-471.4 to -451.9) | -448.8 (-458.6 to -439.0) |
Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 83.8 (80.2 to 87.5) | 82.4 (78.5 to 86.2) |
| Week 8 | 92.6 (90.0 to 95.2) | 91.2 (88.3 to 94.1) |
| Week 12 | 93.4 (90.9 to 95.9) | 91.5 (88.6 to 94.3) |
| Week 16 | 94.5 (92.2 to 96.8) | 92.8 (90.2 to 95.5) |
| Week 20 | 94.8 (92.6 to 97.1) | 93.1 (90.5 to 95.7) |
| Week 24 | 93.7 (91.2 to 96.2) | 92.0 (89.2 to 94.7) |
Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 45.5 (40.6 to 50.5) | 40.3 (35.6 to 45.0) |
| Week 8 | 63.1 (58.3 to 68.0) | 61.7 (56.9 to 66.6) |
| Week 12 | 53.2 (48.3 to 58.2) | 51.0 (46.2 to 55.9) |
| Week 16 | 55.4 (50.5 to 60.3) | 51.9 (46.8 to 56.9) |
| Week 20 | 59.0 (54.0 to 63.9) | 56.5 (51.6 to 61.5) |
| Week 24 | 76.2 (71.9 to 80.5) | 70.8 (66.2 to 75.4) |
Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 66.1 (61.4 to 70.8) | 65.0 (60.3 to 69.7) |
| Week 8 | 89.6 (86.5 to 92.6) | 90.1 (87.0 to 93.1) |
| Week 12 | 94.0 (91.6 to 96.4) | 93.9 (91.5 to 96.4) |
| Week 16 | 95.3 (93.2 to 97.5) | 95.6 (93.5 to 97.7) |
| Week 20 | 95.9 (93.9 to 97.9) | 94.5 (92.2 to 96.8) |
| Week 24 | 96.4 (94.6 to 98.3) | 93.4 (90.8 to 95.9) |
Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Week 4 | 33.0 (28.3 to 37.6) | 29.3 (24.9 to 33.7) |
| Week 8 | 59.3 (54.4 to 64.1) | 59.3 (54.3 to 64.2) |
| Week 12 | 52.7 (47.7 to 57.6) | 50.2 (45.3 to 55.1) |
| Week 16 | 54.9 (49.9 to 59.8) | 51.3 (46.3 to 56.3) |
| Week 20 | 58.2 (53.2 to 63.1) | 55.4 (50.5 to 60.4) |
| Week 24 | 75.1 (70.8 to 79.5) | 68.6 (63.8 to 73.4) |
The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the ANCOVA analysis, the model uses the non-missing change from baseline in BCVA at Weeks 24 as the response variables adjusted for the treatment group, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA score (≥55 and ≤54 letters) and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were not imputed. 95% CI is a rounding of 95.03% CI.
| score on a scale | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) |
|---|---|---|
| Part 1: Change From Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24 | 6.9 (5.8 to 8.0) | 8.1 (7.0 to 9.2) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
| ETDRS Letters | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 13.6 (12.5 to 14.6) | 14.3 (13.3 to 15.4) |
| Week 8 | 15.6 (14.4 to 16.8) | 16.5 (15.4 to 17.7) |
| Week 12 | 17.0 (15.7 to 18.2) | 17.2 (15.9 to 18.4) |
| Week 16 | 16.8 (15.5 to 18.1) | 17.6 (16.2 to 18.9) |
| Week 20 | 17.0 (15.7 to 18.4) | 17.3 (15.9 to 18.6) |
| Week 24 | 16.9 (15.5 to 18.3) | 17.3 (15.9 to 18.8) |
| Week 28 | 16.0 (14.5 to 17.5) | 16.0 (14.4 to 17.5) |
| Week 32 | 17.2 (15.7 to 18.7) | 17.5 (16.0 to 19.0) |
| Week 36 | 17.0 (15.5 to 18.5) | 17.5 (15.9 to 19.0) |
| Week 40 | 15.8 (14.2 to 17.5) | 16.2 (14.5 to 17.9) |
| Week 44 | 16.5 (14.9 to 18.2) | 17.3 (15.7 to 19.0) |
| Week 48 | 16.9 (15.2 to 18.5) | 17.6 (15.9 to 19.3) |
| Week 52 | 16.4 (14.8 to 18.1) | 17.8 (16.2 to 19.5) |
| Week 56 | 16.0 (14.3 to 17.7) | 16.9 (15.2 to 18.6) |
| Week 60 | 16.9 (15.2 to 18.6) | 17.3 (15.6 to 19.0) |
| Week 64 | 16.8 (15.1 to 18.5) | 17.2 (15.5 to 18.9) |
| Week 68 | 16.9 (15.2 to 18.7) | 17.0 (15.2 to 18.7) |
| Week 72 | 16.9 (15.1 to 18.6) | 17.1 (15.3 to 18.8) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 41.5 (36.7 to 46.3) | 45.2 (40.4 to 49.9) |
| Week 8 | 51.1 (46.3 to 55.9) | 53.7 (48.9 to 58.5) |
| Week 12 | 54.6 (49.8 to 59.4) | 55.1 (50.3 to 59.9) |
| Week 16 | 57.7 (52.8 to 62.5) | 59.5 (54.7 to 64.3) |
| Week 20 | 56.6 (51.7 to 61.4) | 57.8 (53.0 to 62.6) |
| Week 24 | 56.6 (51.7 to 61.5) | 58.1 (53.3 to 62.9) |
| Week 28 | 53.3 (48.4 to 58.2) | 54.8 (50.0 to 59.6) |
| Week 32 | 60.9 (56.1 to 65.8) | 57.6 (52.7 to 62.4) |
| Week 36 | 58.2 (53.3 to 63.1) | 58.9 (54.2 to 63.7) |
| Week 40 | 56.6 (51.7 to 61.4) | 55.9 (51.1 to 60.7) |
| Week 44 | 55.7 (50.9 to 60.6) | 57.3 (52.5 to 62.1) |
| Week 48 | 58.8 (53.9 to 63.6) | 58.1 (53.3 to 62.9) |
| Week 52 | 57.6 (52.7 to 62.5) | 58.7 (53.8 to 63.5) |
| Week 56 | 56.3 (51.3 to 61.2) | 57.3 (52.5 to 62.2) |
| Week 60 | 58.2 (53.3 to 63.1) | 59.0 (54.1 to 63.8) |
| Week 64 | 57.1 (52.3 to 61.9) | 59.5 (54.7 to 64.3) |
| Week 68 | 56.8 (52.0 to 61.6) | 59.8 (54.9 to 64.6) |
| Week 72 | 58.7 (53.9 to 63.6) | 60.0 (55.2 to 64.9) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 60.9 (56.0 to 65.8) | 62.3 (57.6 to 66.9) |
| Week 8 | 69.1 (64.5 to 73.7) | 72.8 (68.3 to 77.2) |
| Week 12 | 73.2 (68.8 to 77.7) | 74.7 (70.3 to 79.0) |
| Week 16 | 73.5 (69.1 to 78.0) | 75.8 (71.4 to 80.1) |
| Week 20 | 72.4 (68.0 to 76.9) | 74.1 (69.7 to 78.5) |
| Week 24 | 72.2 (67.7 to 76.6) | 73.3 (68.8 to 77.7) |
| Week 28 | 69.7 (65.1 to 74.3) | 70.5 (66.0 to 75.1) |
| Week 32 | 73.0 (68.5 to 77.4) | 74.4 (70.0 to 78.8) |
| Week 36 | 73.8 (69.3 to 78.2) | 74.9 (70.6 to 79.3) |
| Week 40 | 71.0 (66.5 to 75.6) | 73.0 (68.6 to 77.5) |
| Week 44 | 71.6 (67.1 to 76.1) | 74.1 (69.7 to 78.5) |
| Week 48 | 71.9 (67.3 to 76.4) | 75.5 (71.1 to 79.9) |
| Week 52 | 71.0 (66.4 to 75.6) | 73.8 (69.4 to 78.3) |
| Week 56 | 70.8 (66.2 to 75.3) | 72.2 (67.6 to 76.7) |
| Week 60 | 72.7 (68.2 to 77.2) | 72.5 (67.9 to 77.0) |
| Week 64 | 72.4 (67.9 to 76.9) | 71.6 (67.0 to 76.2) |
| Week 68 | 72.1 (67.7 to 76.6) | 70.5 (65.9 to 75.1) |
| Week 72 | 71.6 (67.1 to 76.1) | 73.0 (68.5 to 77.5) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 83.1 (79.3 to 86.9) | 83.5 (79.7 to 87.2) |
| Week 8 | 85.2 (81.7 to 88.8) | 86.8 (83.3 to 90.2) |
| Week 12 | 87.4 (84.1 to 90.8) | 87.1 (83.7 to 90.5) |
| Week 16 | 86.3 (82.9 to 89.8) | 88.7 (85.5 to 92.0) |
| Week 20 | 84.1 (80.5 to 87.8) | 86.5 (83.0 to 90.0) |
| Week 24 | 85.3 (81.8 to 88.8) | 84.6 (80.9 to 88.2) |
| Week 28 | 81.7 (77.8 to 85.6) | 84.0 (80.3 to 87.7) |
| Week 32 | 84.2 (80.5 to 87.8) | 87.3 (83.9 to 90.7) |
| Week 36 | 84.7 (81.1 to 88.3) | 85.7 (82.1 to 89.3) |
| Week 40 | 82.3 (78.4 to 86.1) | 84.3 (80.6 to 88.0) |
| Week 44 | 82.8 (79.0 to 86.6) | 84.9 (81.2 to 88.5) |
| Week 48 | 83.6 (79.9 to 87.3) | 83.7 (80.0 to 87.5) |
| Week 52 | 80.9 (76.9 to 84.8) | 84.0 (80.3 to 87.8) |
| Week 56 | 79.2 (75.2 to 83.3) | 81.5 (77.6 to 85.5) |
| Week 60 | 82.8 (79.0 to 86.6) | 81.6 (77.6 to 85.5) |
| Week 64 | 80.6 (76.6 to 84.6) | 81.5 (77.6 to 85.5) |
| Week 68 | 83.3 (79.6 to 87.1) | 80.2 (76.1 to 84.2) |
| Week 72 | 83.6 (79.9 to 87.3) | 79.6 (75.5 to 83.7) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 92.1 (89.4 to 94.8) | 95.6 (93.5 to 97.7) |
| Week 8 | 92.1 (89.4 to 94.8) | 94.8 (92.5 to 97.0) |
| Week 12 | 93.2 (90.6 to 95.7) | 92.6 (89.9 to 95.2) |
| Week 16 | 92.6 (90.0 to 95.3) | 92.0 (89.3 to 94.8) |
| Week 20 | 90.5 (87.5 to 93.4) | 91.4 (88.6 to 94.3) |
| Week 24 | 90.5 (87.5 to 93.4) | 89.2 (86.1 to 92.4) |
| Week 28 | 88.0 (84.7 to 91.3) | 88.4 (85.2 to 91.7) |
| Week 32 | 89.4 (86.2 to 92.5) | 92.0 (89.2 to 94.8) |
| Week 36 | 89.9 (86.9 to 93.0) | 90.1 (87.0 to 93.1) |
| Week 40 | 87.7 (84.5 to 91.0) | 88.7 (85.5 to 91.9) |
| Week 44 | 88.5 (85.3 to 91.7) | 89.2 (86.1 to 92.4) |
| Week 48 | 88.5 (85.3 to 91.7) | 88.7 (85.5 to 91.9) |
| Week 52 | 85.8 (82.2 to 89.3) | 89.0 (85.8 to 92.2) |
| Week 56 | 85.8 (82.3 to 89.3) | 87.3 (83.9 to 90.7) |
| Week 60 | 86.6 (83.2 to 90.0) | 87.3 (83.9 to 90.7) |
| Week 64 | 86.1 (82.6 to 89.6) | 86.2 (82.7 to 89.7) |
| Week 68 | 87.4 (84.1 to 90.8) | 85.4 (81.8 to 89.0) |
| Week 72 | 86.6 (83.2 to 90.1) | 85.7 (82.1 to 89.2) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 98.4 (97.1 to 99.7) | 98.9 (97.8 to 100.0) |
| Week 8 | 98.1 (96.7 to 99.5) | 98.1 (96.7 to 99.5) |
| Week 12 | 98.6 (97.5 to 99.8) | 97.5 (95.9 to 99.1) |
| Week 16 | 97.3 (95.6 to 98.9) | 97.0 (95.2 to 98.7) |
| Week 20 | 97.0 (95.3 to 98.7) | 96.7 (94.9 to 98.5) |
| Week 24 | 96.2 (94.3 to 98.1) | 96.7 (94.9 to 98.5) |
| Week 28 | 95.6 (93.6 to 97.7) | 94.2 (91.8 to 96.6) |
| Week 32 | 95.4 (93.3 to 97.5) | 96.1 (94.2 to 98.1) |
| Week 36 | 95.4 (93.3 to 97.5) | 95.9 (93.8 to 97.9) |
| Week 40 | 94.0 (91.6 to 96.4) | 95.9 (93.8 to 97.9) |
| Week 44 | 94.0 (91.6 to 96.4) | 95.6 (93.5 to 97.7) |
| Week 48 | 94.0 (91.6 to 96.4) | 95.6 (93.5 to 97.7) |
| Week 52 | 94.6 (92.3 to 96.8) | 96.7 (94.9 to 98.5) |
| Week 56 | 95.1 (92.9 to 97.3) | 95.6 (93.5 to 97.7) |
| Week 60 | 93.5 (91.0 to 96.0) | 95.3 (93.2 to 97.5) |
| Week 64 | 94.0 (91.6 to 96.4) | 94.8 (92.5 to 97.0) |
| Week 68 | 93.5 (90.9 to 96.0) | 95.9 (93.8 to 97.9) |
| Week 72 | 93.2 (90.6 to 95.7) | 95.0 (92.8 to 97.2) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 98.1 (96.7 to 99.5) | 98.6 (97.4 to 99.8) |
| Week 8 | 97.5 (96.0 to 99.1) | 97.5 (95.9 to 99.1) |
| Week 12 | 97.8 (96.3 to 99.3) | 97.0 (95.2 to 98.7) |
| Week 16 | 95.9 (93.9 to 97.9) | 96.1 (94.2 to 98.1) |
| Week 20 | 96.7 (94.9 to 98.5) | 96.1 (94.2 to 98.1) |
| Week 24 | 95.1 (92.9 to 97.3) | 95.9 (93.8 to 97.9) |
| Week 28 | 94.6 (92.3 to 96.9) | 93.4 (90.9 to 95.9) |
| Week 32 | 94.3 (91.9 to 96.6) | 95.9 (93.8 to 97.9) |
| Week 36 | 94.3 (91.9 to 96.6) | 95.0 (92.8 to 97.3) |
| Week 40 | 92.9 (90.3 to 95.5) | 93.9 (91.5 to 96.4) |
| Week 44 | 93.2 (90.7 to 95.7) | 94.5 (92.2 to 96.8) |
| Week 48 | 92.4 (89.7 to 95.0) | 93.9 (91.5 to 96.4) |
| Week 52 | 92.9 (90.3 to 95.5) | 95.0 (92.8 to 97.2) |
| Week 56 | 91.3 (88.4 to 94.1) | 93.6 (91.2 to 96.1) |
| Week 60 | 92.1 (89.4 to 94.8) | 94.5 (92.2 to 96.8) |
| Week 64 | 92.9 (90.3 to 95.5) | 93.9 (91.5 to 96.4) |
| Week 68 | 92.6 (90.0 to 95.3) | 94.2 (91.8 to 96.6) |
| Week 72 | 92.6 (90.0 to 95.3) | 93.7 (91.2 to 96.1) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 97.0 (95.3 to 98.7) | 98.1 (96.7 to 99.5) |
| Week 8 | 96.2 (94.2 to 98.1) | 96.4 (94.5 to 98.3) |
| Week 12 | 95.9 (93.9 to 97.9) | 96.1 (94.2 to 98.1) |
| Week 16 | 95.4 (93.2 to 97.5) | 94.8 (92.5 to 97.0) |
| Week 20 | 94.8 (92.6 to 97.1) | 93.9 (91.5 to 96.4) |
| Week 24 | 94.0 (91.6 to 96.4) | 93.7 (91.2 to 96.1) |
| Week 28 | 92.4 (89.7 to 95.1) | 91.7 (88.9 to 94.5) |
| Week 32 | 91.3 (88.4 to 94.1) | 94.8 (92.5 to 97.0) |
| Week 36 | 92.7 (90.0 to 95.3) | 94.2 (91.8 to 96.6) |
| Week 40 | 91.0 (88.1 to 93.9) | 92.6 (89.9 to 95.2) |
| Week 44 | 90.7 (87.8 to 93.6) | 92.8 (90.2 to 95.4) |
| Week 48 | 91.0 (88.1 to 93.9) | 92.6 (89.9 to 95.2) |
| Week 52 | 90.5 (87.5 to 93.4) | 93.4 (90.9 to 95.9) |
| Week 56 | 88.5 (85.3 to 91.7) | 91.4 (88.6 to 94.3) |
| Week 60 | 90.5 (87.5 to 93.4) | 92.3 (89.6 to 95.0) |
| Week 64 | 90.7 (87.8 to 93.7) | 91.2 (88.3 to 94.1) |
| Week 68 | 89.6 (86.6 to 92.7) | 91.7 (88.9 to 94.5) |
| Week 72 | 90.5 (87.5 to 93.4) | 90.6 (87.7 to 93.6) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 6.0 (3.6 to 8.4) | 4.7 (2.6 to 6.8) |
| Week 8 | 8.7 (5.9 to 11.5) | 10.2 (7.2 to 13.2) |
| Week 12 | 10.9 (7.8 to 14.0) | 11.9 (8.7 to 15.0) |
| Week 16 | 11.5 (8.4 to 14.6) | 14.1 (10.7 to 17.5) |
| Week 20 | 14.2 (10.9 to 17.6) | 14.9 (11.4 to 18.3) |
| Week 24 | 14.5 (11.0 to 17.9) | 15.2 (11.7 to 18.7) |
| Week 28 | 9.8 (6.9 to 12.8) | 12.7 (9.5 to 15.9) |
| Week 32 | 13.4 (10.0 to 16.7) | 14.9 (11.4 to 18.3) |
| Week 36 | 15.3 (11.8 to 18.8) | 14.9 (11.5 to 18.3) |
| Week 40 | 14.8 (11.3 to 18.2) | 12.4 (9.2 to 15.7) |
| Week 44 | 15.5 (12.0 to 19.1) | 14.1 (10.7 to 17.5) |
| Week 48 | 15.0 (11.6 to 18.5) | 14.6 (11.2 to 18.0) |
| Week 52 | 16.7 (13.0 to 20.3) | 14.9 (11.4 to 18.4) |
| Week 56 | 14.8 (11.3 to 18.2) | 15.5 (12.0 to 18.9) |
| Week 60 | 15.8 (12.3 to 19.4) | 16.3 (12.7 to 19.9) |
| Week 64 | 16.1 (12.5 to 19.8) | 15.7 (12.2 to 19.3) |
| Week 68 | 15.3 (11.8 to 18.9) | 15.2 (11.7 to 18.7) |
| Week 72 | 15.3 (11.8 to 18.8) | 14.4 (11.0 to 17.7) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 45.0 (41.0 to 49.1) | 46.1 (41.9 to 50.2) |
| Week 8 | 48.6 (44.3 to 52.8) | 54.6 (50.5 to 58.7) |
| Week 12 | 54.9 (50.8 to 58.9) | 55.7 (51.4 to 60.0) |
| Week 16 | 54.9 (50.6 to 59.1) | 59.3 (55.2 to 63.4) |
| Week 20 | 54.1 (49.7 to 58.4) | 57.6 (53.4 to 61.8) |
| Week 24 | 55.7 (51.3 to 60.0) | 59.0 (54.5 to 63.4) |
| Week 28 | 53.2 (48.8 to 57.7) | 56.2 (51.8 to 60.7) |
| Week 32 | 56.0 (51.6 to 60.4) | 60.4 (56.1 to 64.6) |
| Week 36 | 53.8 (49.4 to 58.2) | 60.7 (56.3 to 65.0) |
| Week 40 | 51.9 (47.3 to 56.4) | 56.2 (51.7 to 60.8) |
| Week 44 | 53.0 (48.4 to 57.6) | 60.9 (56.5 to 65.3) |
| Week 48 | 56.2 (51.8 to 60.7) | 60.6 (56.2 to 65.1) |
| Week 52 | 54.3 (49.8 to 58.9) | 60.4 (55.9 to 64.8) |
| Week 56 | 51.9 (47.3 to 56.4) | 58.7 (54.3 to 63.2) |
| Week 60 | 56.0 (51.5 to 60.4) | 58.7 (54.3 to 63.1) |
| Week 64 | 56.5 (52.1 to 61.0) | 57.9 (53.4 to 62.4) |
| Week 68 | 56.0 (51.5 to 60.4) | 57.9 (53.4 to 62.4) |
| Week 72 | 56.2 (51.7 to 60.8) | 58.5 (53.9 to 63.1) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\>38 and ≤38 letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 10.0 (7.3 to 12.8) | 8.6 (6.1 to 11.1) |
| Week 8 | 8.2 (5.5 to 10.8) | 7.0 (4.6 to 9.4) |
| Week 12 | 7.3 (4.9 to 9.8) | 6.4 (4.0 to 8.8) |
| Week 16 | 7.8 (5.3 to 10.4) | 6.2 (3.8 to 8.5) |
| Week 20 | 8.4 (5.7 to 11.0) | 6.4 (4.0 to 8.8) |
| Week 24 | 10.1 (7.1 to 13.0) | 7.5 (4.9 to 10.1) |
| Week 28 | 8.9 (6.1 to 11.7) | 9.4 (6.6 to 12.3) |
| Week 32 | 9.2 (6.4 to 12.0) | 8.0 (5.4 to 10.7) |
| Week 36 | 9.5 (6.6 to 12.4) | 8.3 (5.7 to 11.0) |
| Week 40 | 9.8 (6.8 to 12.7) | 7.5 (4.9 to 10.1) |
| Week 44 | 10.6 (7.5 to 13.6) | 8.3 (5.6 to 11.0) |
| Week 48 | 10.0 (7.1 to 13.0) | 7.5 (4.9 to 10.1) |
| Week 52 | 11.4 (8.3 to 14.5) | 7.2 (4.7 to 9.8) |
| Week 56 | 11.9 (8.8 to 15.1) | 8.6 (5.8 to 11.4) |
| Week 60 | 11.4 (8.3 to 14.5) | 8.3 (5.7 to 11.0) |
| Week 64 | 11.1 (8.0 to 14.2) | 8.3 (5.6 to 11.0) |
| Week 68 | 11.2 (8.0 to 14.3) | 8.3 (5.6 to 11.0) |
| Week 72 | 11.4 (8.3 to 14.6) | 8.0 (5.4 to 10.7) |
The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the MMRM analysis, the model adjusted for the treatment group, visit, visit-by-treatment group interaction, baseline NEI VFQ-25 Composite Score continuous), baseline BCVA score (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were implicitly imputed. Invalid BCVA values were excluded. 95% CI is a rounding of 95.03% CI.
| score on a scale | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 24 | 7.0 (5.9 to 8.0) | 8.2 (7.1 to 9.3) |
| Week 48 | 7.0 (5.9 to 8.2) | 8.3 (7.1 to 9.5) |
| Week 72 | 7.8 (6.5 to 9.0) | 8.5 (7.3 to 9.8) |
Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
| microns | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | -422.1 (-430.6 to -413.7) | -418.2 (-426.6 to -409.7) |
| Week 8 | -445.1 (-453.6 to -436.6) | -438.5 (-447.0 to -429.9) |
| Week 12 | -452.3 (-461.8 to -442.8) | -443.7 (-453.2 to -434.1) |
| Week 16 | -453.8 (-463.1 to -444.5) | -446.2 (-455.5 to -436.9) |
| Week 20 | -460.0 (-468.1 to -451.8) | -447.1 (-455.4 to -438.9) |
| Week 24 | -462.3 (-472.3 to -452.3) | -447.8 (-457.9 to -437.8) |
| Week 28 | -415.5 (-431.8 to -399.1) | -413.7 (-430.3 to -397.2) |
| Week 32 | -459.4 (-468.7 to -450.1) | -445.8 (-455.3 to -436.3) |
| Week 36 | -451.7 (-462.7 to -440.8) | -441.8 (-452.9 to -430.8) |
| Week 40 | -409.8 (-425.6 to -394.0) | -414.0 (-429.9 to -398.0) |
| Week 44 | -456.6 (-467.1 to -446.0) | -449.8 (-460.6 to -439.0) |
| Week 48 | -461.2 (-471.3 to -451.1) | -448.0 (-458.3 to -437.7) |
| Week 52 | -446.0 (-457.0 to -435.0) | -451.8 (-462.9 to -440.7) |
| Week 56 | -435.9 (-449.8 to -422.0) | -426.2 (-440.3 to -412.1) |
| Week 60 | -468.2 (-476.8 to -459.5) | -458.9 (-467.6 to -450.1) |
| Week 64 | -466.6 (-473.7 to -459.5) | -465.5 (-472.6 to -458.3) |
| Week 68 | -467.5 (-476.0 to -459.1) | -457.7 (-466.2 to -449.2) |
| Week 72 | -463.5 (-472.8 to -454.3) | -458.6 (-467.9 to -449.2) |
Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 83.8 (80.2 to 87.5) | 82.4 (78.5 to 86.2) |
| Week 8 | 92.6 (90.0 to 95.2) | 91.2 (88.3 to 94.1) |
| Week 12 | 93.4 (90.9 to 95.9) | 91.5 (88.6 to 94.3) |
| Week 16 | 94.5 (92.2 to 96.8) | 92.8 (90.2 to 95.5) |
| Week 20 | 94.5 (92.2 to 96.8) | 93.1 (90.5 to 95.7) |
| Week 24 | 93.7 (91.2 to 96.2) | 91.7 (88.9 to 94.5) |
| Week 28 | 82.5 (78.6 to 86.4) | 84.0 (80.3 to 87.7) |
| Week 32 | 93.2 (90.6 to 95.7) | 90.3 (87.4 to 93.3) |
| Week 36 | 91.8 (89.0 to 94.6) | 89.5 (86.4 to 92.6) |
| Week 40 | 80.0 (76.0 to 84.1) | 80.7 (76.7 to 84.7) |
| Week 44 | 93.2 (90.6 to 95.7) | 90.9 (88.0 to 93.8) |
| Week 48 | 92.6 (89.9 to 95.3) | 89.8 (86.7 to 92.9) |
| Week 52 | 88.5 (85.2 to 91.8) | 90.9 (88.0 to 93.8) |
| Week 56 | 87.4 (84.1 to 90.8) | 84.3 (80.6 to 88.0) |
| Week 60 | 93.7 (91.3 to 96.2) | 92.8 (90.2 to 95.5) |
| Week 64 | 94.3 (91.9 to 96.6) | 93.4 (90.8 to 95.9) |
| Week 68 | 93.2 (90.6 to 95.7) | 91.4 (88.6 to 94.3) |
| Week 72 | 92.4 (89.6 to 95.1) | 91.2 (88.3 to 94.0) |
Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 45.5 (40.6 to 50.5) | 40.6 (35.8 to 45.3) |
| Week 8 | 63.1 (58.3 to 68.0) | 61.7 (56.9 to 66.6) |
| Week 12 | 53.2 (48.3 to 58.2) | 51.0 (46.2 to 55.9) |
| Week 16 | 55.4 (50.5 to 60.3) | 51.9 (46.8 to 56.9) |
| Week 20 | 59.0 (54.0 to 63.9) | 56.5 (51.6 to 61.5) |
| Week 24 | 77.0 (72.8 to 81.3) | 70.8 (66.2 to 75.4) |
| Week 28 | 53.8 (48.7 to 58.9) | 51.5 (46.4 to 56.6) |
| Week 32 | 67.7 (63.1 to 72.4) | 67.2 (62.5 to 72.0) |
| Week 36 | 62.8 (58.1 to 67.5) | 57.6 (52.6 to 62.6) |
| Week 40 | 52.7 (47.7 to 57.7) | 51.0 (46.0 to 56.1) |
| Week 44 | 66.4 (61.6 to 71.2) | 63.4 (58.5 to 68.3) |
| Week 48 | 74.3 (69.9 to 78.8) | 69.7 (65.0 to 74.3) |
| Week 52 | 66.9 (62.2 to 71.6) | 63.4 (58.5 to 68.2) |
| Week 56 | 60.9 (56.0 to 65.9) | 58.7 (53.7 to 63.6) |
| Week 60 | 71.6 (67.0 to 76.1) | 72.7 (68.2 to 77.2) |
| Week 64 | 76.5 (72.2 to 80.8) | 72.7 (68.2 to 77.2) |
| Week 68 | 74.6 (70.2 to 79.0) | 71.3 (66.8 to 75.9) |
| Week 72 | 78.1 (73.9 to 82.3) | 74.4 (69.9 to 78.9) |
Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 66.1 (61.4 to 70.8) | 65.0 (60.3 to 69.7) |
| Week 8 | 89.6 (86.5 to 92.6) | 90.1 (87.0 to 93.1) |
| Week 12 | 94.0 (91.6 to 96.4) | 93.9 (91.5 to 96.4) |
| Week 16 | 95.3 (93.2 to 97.5) | 95.6 (93.5 to 97.7) |
| Week 20 | 95.9 (93.9 to 97.9) | 94.5 (92.2 to 96.8) |
| Week 24 | 96.2 (94.2 to 98.1) | 93.4 (90.8 to 95.9) |
| Week 28 | 89.3 (86.2 to 92.5) | 90.1 (87.0 to 93.1) |
| Week 32 | 95.6 (93.6 to 97.7) | 94.5 (92.2 to 96.8) |
| Week 36 | 95.1 (92.9 to 97.3) | 92.3 (89.6 to 95.0) |
| Week 40 | 89.6 (86.5 to 92.7) | 89.3 (86.1 to 92.4) |
| Week 44 | 95.4 (93.2 to 97.5) | 92.8 (90.2 to 95.5) |
| Week 48 | 93.4 (90.9 to 95.9) | 89.5 (86.4 to 92.6) |
| Week 52 | 92.6 (89.9 to 95.3) | 93.6 (91.2 to 96.1) |
| Week 56 | 93.4 (90.9 to 95.9) | 90.1 (87.1 to 93.1) |
| Week 60 | 97.0 (95.3 to 98.7) | 94.8 (92.5 to 97.0) |
| Week 64 | 96.7 (94.9 to 98.5) | 95.9 (93.8 to 97.9) |
| Week 68 | 97.6 (96.0 to 99.1) | 93.9 (91.6 to 96.3) |
| Week 72 | 95.4 (93.2 to 97.5) | 93.1 (90.6 to 95.7) |
Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Week 4 | 33.0 (28.3 to 37.6) | 29.3 (24.9 to 33.7) |
| Week 8 | 59.3 (54.4 to 64.1) | 59.3 (54.3 to 64.2) |
| Week 12 | 52.7 (47.7 to 57.6) | 50.2 (45.3 to 55.1) |
| Week 16 | 54.9 (49.9 to 59.8) | 51.3 (46.3 to 56.3) |
| Week 20 | 58.2 (53.2 to 63.1) | 55.4 (50.5 to 60.4) |
| Week 24 | 76.0 (71.6 to 80.3) | 68.6 (63.8 to 73.4) |
| Week 28 | 52.7 (47.6 to 57.8) | 51.2 (46.1 to 56.3) |
| Week 32 | 67.2 (62.6 to 71.8) | 66.4 (61.6 to 71.2) |
| Week 36 | 62.8 (58.1 to 67.5) | 56.5 (51.5 to 61.5) |
| Week 40 | 52.7 (47.7 to 57.7) | 50.2 (45.1 to 55.2) |
| Week 44 | 64.7 (59.9 to 69.6) | 60.9 (56.0 to 65.8) |
| Week 48 | 70.8 (66.1 to 75.4) | 65.8 (61.0 to 70.6) |
| Week 52 | 65.8 (61.1 to 70.6) | 61.7 (56.8 to 66.6) |
| Week 56 | 60.7 (55.7 to 65.6) | 58.1 (53.2 to 63.0) |
| Week 60 | 71.0 (66.4 to 75.6) | 71.6 (67.0 to 76.2) |
| Week 64 | 75.4 (71.1 to 79.8) | 71.9 (67.3 to 76.4) |
| Week 68 | 74.3 (69.9 to 78.8) | 70.8 (66.2 to 75.3) |
| Week 72 | 77.0 (72.8 to 81.3) | 71.6 (67.0 to 76.3) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.
| ETDRS Letters | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|
| Week 28 | -0.8 (-1.6 to 0.0) | -1.2 (-2.0 to -0.4) |
| Week 32 | 0.2 (-0.6 to 0.9) | 0.2 (-0.6 to 1.0) |
| Week 36 | -0.1 (-0.8 to 0.7) | 0.1 (-0.7 to 0.9) |
| Week 40 | -1.3 (-2.4 to -0.2) | -1.4 (-2.4 to -0.3) |
| Week 44 | -0.6 (-1.6 to 0.4) | 0.0 (-1.0 to 1.0) |
| Week 48 | -0.1 (-1.1 to 0.9) | 0.2 (-0.8 to 1.1) |
| Week 52 | -0.6 (-1.6 to 0.4) | 0.3 (-0.6 to 1.3) |
| Week 56 | -1.1 (-2.1 to 0.0) | -0.6 (-1.7 to 0.5) |
| Week 60 | 0.0 (-1.1 to 1.0) | -0.1 (-1.2 to 0.9) |
| Week 64 | -0.2 (-1.3 to 0.8) | -0.2 (-1.3 to 0.9) |
| Week 68 | -0.1 (-1.2 to 1.0) | -0.5 (-1.6 to 0.6) |
| Week 72 | -0.2 (-1.3 to 1.0) | -0.3 (-1.5 to 0.8) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|
| Week 28 | 86.3 (82.9 to 89.8) | 83.8 (80.0 to 87.5) |
| Week 32 | 88.8 (85.6 to 92.0) | 87.9 (84.6 to 91.2) |
| Week 36 | 89.3 (86.2 to 92.5) | 87.9 (84.6 to 91.2) |
| Week 40 | 87.4 (84.0 to 90.8) | 86.0 (82.4 to 89.5) |
| Week 44 | 87.4 (84.0 to 90.8) | 88.4 (85.2 to 91.7) |
| Week 48 | 88.5 (85.3 to 91.7) | 87.3 (83.9 to 90.7) |
| Week 52 | 86.3 (82.8 to 89.8) | 87.6 (84.2 to 91.0) |
| Week 56 | 85.7 (82.2 to 89.3) | 85.4 (81.8 to 89.0) |
| Week 60 | 87.7 (84.3 to 91.0) | 86.2 (82.7 to 89.8) |
| Week 64 | 86.3 (82.8 to 89.8) | 85.9 (82.4 to 89.5) |
| Week 68 | 87.1 (83.7 to 90.5) | 85.4 (81.8 to 89.0) |
| Week 72 | 86.6 (83.1 to 90.0) | 84.0 (80.3 to 87.8) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|
| Week 28 | 82.8 (79.0 to 86.6) | 81.3 (77.3 to 85.2) |
| Week 32 | 87.1 (83.7 to 90.6) | 86.0 (82.4 to 89.5) |
| Week 36 | 84.7 (81.0 to 88.4) | 85.4 (81.8 to 89.0) |
| Week 40 | 82.8 (78.9 to 86.6) | 81.6 (77.6 to 85.5) |
| Week 44 | 84.1 (80.4 to 87.9) | 86.8 (83.4 to 90.2) |
| Week 48 | 84.4 (80.7 to 88.1) | 84.8 (81.2 to 88.5) |
| Week 52 | 82.8 (78.9 to 86.6) | 85.4 (81.8 to 89.0) |
| Week 56 | 80.0 (76.0 to 84.1) | 81.8 (77.9 to 85.8) |
| Week 60 | 83.6 (79.8 to 87.4) | 82.6 (78.8 to 86.5) |
| Week 64 | 81.7 (77.7 to 85.6) | 83.2 (79.4 to 87.0) |
| Week 68 | 82.2 (78.3 to 86.1) | 80.7 (76.7 to 84.7) |
| Week 72 | 82.5 (78.6 to 86.3) | 80.7 (76.7 to 84.7) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|
| Week 28 | 72.7 (68.2 to 77.2) | 69.7 (65.0 to 74.4) |
| Week 32 | 78.4 (74.2 to 82.6) | 75.5 (71.1 to 79.9) |
| Week 36 | 74.1 (69.6 to 78.5) | 80.2 (76.1 to 84.2) |
| Week 40 | 71.0 (66.4 to 75.6) | 71.6 (67.0 to 76.2) |
| Week 44 | 73.7 (69.3 to 78.2) | 73.0 (68.5 to 77.6) |
| Week 48 | 76.5 (72.2 to 80.8) | 74.1 (69.6 to 78.6) |
| Week 52 | 71.3 (66.7 to 75.9) | 74.1 (69.6 to 78.6) |
| Week 56 | 69.4 (64.7 to 74.1) | 68.3 (63.6 to 73.1) |
| Week 60 | 74.3 (69.8 to 78.7) | 71.6 (67.0 to 76.2) |
| Week 64 | 74.6 (70.1 to 79.0) | 71.6 (67.0 to 76.2) |
| Week 68 | 73.2 (68.7 to 77.7) | 69.2 (64.5 to 73.8) |
| Week 72 | 72.9 (68.4 to 77.5) | 70.3 (65.6 to 74.9) |
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.
| Percentage of participants | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|
| Week 28 | 48.9 (43.8 to 54.0) | 45.4 (40.4 to 50.5) |
| Week 32 | 56.0 (50.9 to 61.1) | 52.9 (47.8 to 58.0) |
| Week 36 | 55.5 (50.4 to 60.5) | 55.1 (50.0 to 60.2) |
| Week 40 | 53.0 (47.9 to 58.0) | 48.2 (43.1 to 53.3) |
| Week 44 | 53.0 (47.9 to 58.0) | 54.0 (49.0 to 59.1) |
| Week 48 | 56.5 (51.5 to 61.6) | 53.5 (48.4 to 58.6) |
| Week 52 | 56.0 (50.9 to 61.1) | 56.5 (51.4 to 61.5) |
| Week 56 | 54.9 (49.8 to 60.0) | 53.2 (48.1 to 58.2) |
| Week 60 | 55.9 (50.9 to 61.0) | 51.0 (45.9 to 56.1) |
| Week 64 | 54.6 (49.5 to 59.7) | 52.1 (47.0 to 57.2) |
| Week 68 | 55.4 (50.4 to 60.4) | 52.3 (47.3 to 57.4) |
| Week 72 | 55.4 (50.4 to 60.5) | 52.7 (47.6 to 57.7) |
In Part 2 of the study, participants in both the faricimab Q4W and aflibercept Q4W arms in Part 1 received 6 mg faricimab intravitreal injections administered according to a personalized treatment interval (PTI) dosing regimen in intervals between Q4W and Q16W. At faricimab dosing visits, treatment intervals were maintained or adjusted (i.e., increased by 4 weeks or decreased by 4, 8, or 12 weeks), based on central subfield thickness (CST) and BCVA values.
| Percentage of participants | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|
| Once Every 4 Weeks (Q4W) | 34.5 (29.4 to 39.7) | 32.4 (27.2 to 37.6) |
| Once Every 8 Weeks (Q8W) | 20.0 (15.7 to 24.3) | 17.5 (13.3 to 21.7) |
| Once Every 12 Weeks (Q12W) | 8.5 (5.5 to 11.5) | 11.1 (7.6 to 14.6) |
| Once Every 16 Weeks (Q16W) | 37.0 (31.8 to 42.2) | 39.0 (33.7 to 44.4) |
| Injections | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|
| Part 2: Number of Study Drug Injections Received in the Study Eye From Week 24 Through Week 72 | 5.0 (1 to 12) | 4.0 (1 to 12) |
This analysis of adverse events (AEs) only includes ocular AEs that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).
| Participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|---|---|
| Adverse Event (AE) | 89 | 98 | 130 | 118 |
| AE by Severity: Mild | 65 | 65 | 63 | 69 |
| AE by Severity: Moderate | 18 | 27 | 52 | 43 |
| AE by Severity: Severe | 6 | 6 | 15 | 6 |
| Serious Adverse Event (SAE) | 9 | 13 | 26 | 12 |
| AE Leading to Withdrawal from Study Treatment | 3 | 2 | 5 | 3 |
| Treatment Related AEs | 15 | 6 | 14 | 11 |
| Treatment Related SAEs | 3 | 2 | 4 | 0 |
| Any AE of Special Interest (AESI) | 8 | 12 | 21 | 9 |
| AESI: Drop in Visual Acuity Score ≥30 | 6 | 6 | 15 | 7 |
| AESI: Associated with Severe IOI | 0 | 0 | 0 | 1 |
| AESI: Intervention Req. to Prevent Permanent Vision Loss | 2 | 6 | 6 | 1 |
This analysis of adverse events (AEs) only includes ocular AEs that occurred in the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).
| Participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|---|---|
| Adverse Event (AE) | 31 | 33 | 70 | 51 |
| Serious Adverse Event (SAE) | 1 | 1 | 1 | 0 |
| Any AE of Special Interest (AESI) | 1 | 1 | 1 | 0 |
| AESI: Drop in Visual Acuity Score ≥30 | 1 | 1 | 1 | 0 |
This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.
| Participants | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|---|---|
| Adverse Event (AE) | 123 | 134 | 191 | 174 |
| Serious Adverse Event (SAE) | 22 | 23 | 30 | 41 |
| AE Leading to Withdrawal from Study Treatment | 0 | 1 | 3 | 3 |
| Any AE of Special Interest (AESI) | 0 | 0 | 0 | 0 |
| microgram per millilitre (μg/mL) | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) |
|---|---|---|
| Baseline | 0.0001 ± 0.0009 | — |
| Week 4 | 0.0222 ± 0.0176 | — |
| Week 24 | 0.0257 ± 0.0217 | 0.0005 ± 0.0014 |
| Week 28 | 0.0055 ± 0.0086 | 0.0026 ± 0.0084 |
| Week 52 | 0.0089 ± 0.0142 | 0.0090 ± 0.0136 |
| Week 72 | 0.0087 ± 0.0140 | 0.0099 ± 0.0167 |
Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The number of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period. Treatment-unaffected ADA-positive is a post-baseline sample with a titer that is lower than 4-fold the ADA-positive baseline titer (faricimab arm) or the ADA-positive titer prior to first faricimab injection (aflibercept arm).
| Participants | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) | All Faricimab Participants |
|---|---|---|---|
| Baseline (BL): Total ADA-Positive | 4 | 5 | 9 |
| Post-BL: Total ADA-Positive | 62 | 27 | 89 |
| Post-BL: Treatment-Emergent ADA-Positive | 60 | 23 | 83 |
| Post-BL: Treatment-Unaffected ADA-Positive | 2 | 4 | 6 |
Collected over Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Faricimab Q4W (Part 1) | 1/365 (0.3%) | 32/365 (8.8%) | 67/365 (18.4%) |
| Arm B: Aflibercept Q4W (Part 1) | 2/361 (0.6%) | 34/361 (9.4%) | 66/361 (18.3%) |
| Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | 4/359 (1.1%) | 55/359 (15.3%) | 109/359 (30.4%) |
| Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) | 1/342 (0.3%) | 51/342 (14.9%) | 118/342 (34.5%) |
| Event | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|---|---|
| Cystoid macular oedemaEye disorders | 2/365 | 2/361 | 5/359 | 1/342 |
| Retinal vein occlusionEye disorders | 2/365 | 2/361 | 5/359 | 3/342 |
| Macular oedemaEye disorders | 0/365 | 1/361 | 4/359 | 0/342 |
| Myocardial infarctionCardiac disorders | 0/365 | 3/361 | 3/359 | 0/342 |
| PneumoniaInfections and infestations | 2/365 | 1/361 | 3/359 | 2/342 |
| COVID-19Infections and infestations | 3/365 | 0/361 | 1/359 | 0/342 |
| Acute myocardial infarctionCardiac disorders | 1/365 | 1/361 | 0/359 | 2/342 |
| Retinal artery occlusionEye disorders | 2/365 | 1/361 | 0/359 | 2/342 |
| SepsisInfections and infestations | 1/365 | 0/361 | 0/359 | 2/342 |
| Atrial fibrillationCardiac disorders | 0/365 | 0/361 | 2/359 | 2/342 |
| Event | Arm A: Faricimab Q4W (Part 1) | Arm B: Aflibercept Q4W (Part 1) | Arm A: Faricimab Q4W to Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W to Faricimab PTI (Part 2) |
|---|---|---|---|---|
| COVID-19Infections and infestations | 14/365 | 12/361 | 42/359 | 46/342 |
| NasopharyngitisInfections and infestations | 5/365 | 7/361 | 10/359 | 16/342 |
| Intraocular pressure increasedInvestigations | 9/365 | 12/361 | 16/359 | 15/342 |
| HypertensionVascular disorders | 15/365 | 10/361 | 12/359 | 8/342 |
| Vitreous detachmentEye disorders | 11/365 | 9/361 | 6/359 | 14/342 |
| CataractEye disorders | 3/365 | 7/361 | 14/359 | 14/342 |
| Macular oedemaEye disorders | 2/365 | 0/361 | 7/359 | 14/342 |
| Conjunctival haemorrhageEye disorders | 10/365 | 14/361 | 10/359 | 7/342 |
| Epiretinal membraneEye disorders | 3/365 | 2/361 | 3/359 | 11/342 |
| Cystoid macular oedemaEye disorders | 1/365 | 3/361 | 11/359 | 10/342 |
ITT Population: All global participants who were randomized in the study, according to the assigned treatment.
| Age, Continuous(Years) | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) | Total |
|---|---|---|---|
| Mean | 65.6 ± 13.1 | 64.7 ± 13.3 | 65.1 ± 13.2 |
| Sex: Female, Male(Participants) | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) | Total |
|---|---|---|---|
| Female | 173 | 163 | 336 |
| Male | 193 | 200 | 393 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) | Total |
|---|---|---|---|
| Hispanic or Latino | 66 | 73 | 139 |
| Not Hispanic or Latino | 286 | 283 | 569 |
| Unknown or Not Reported | 14 | 7 | 21 |
| Race (NIH/OMB)(Participants) | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 3 | 5 |
| Asian | 89 | 88 | 177 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 10 | 13 | 23 |
| White | 243 | 253 | 496 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 21 | 5 | 26 |
| Region of Enrollment(Participants) | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) | Total |
|---|---|---|---|
| Rest of World | 187 | 187 | 374 |
| USA and Canada | 95 | 93 | 188 |
| Asia | 84 | 83 | 167 |
| Number of Participants by the Eye (Left or Right) Chosen as the Study Eye(Participants) | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) | Total |
|---|---|---|---|
| Left Eye | 180 | 181 | 361 |
| Right Eye | 186 | 182 | 368 |
| Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye(ETDRS Letters) | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) | Total |
|---|---|---|---|
| Mean | 50.25 ± 16.25 | 50.71 ± 16.34 | 50.48 ± 16.29 |
| Number of Participants by the BCVA Letter Score Categories in the Study Eye(Participants) | Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) | Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) | Total |
|---|---|---|---|
| ≤34 Letters (20/200 or Worse) | 79 | 80 | 159 |
| >34 Letters to <55 Letters | 106 | 105 | 211 |
| ≥55 Letters (20/80 or Better) | 181 | 178 | 359 |
Showing the first 100 of 194 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Mar 2021 to primary completion in Aug 2022, 17 months.
Results were first posted in Jan 2024, 1 year 5 months after primary completion. A results delay was requested in Jun 2023.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 17 months is below that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab